Prognostic Relevance of Urokinase Plasminogen Activator in Breast Cancer
Author Information
Author(s): E-F Solomayer, IJ Diel, D Wallwiener, S Bode, G Meyberg, M Sillem, Ch Gollan, MD Kramer, U Krainick, G Bastert
Primary Institution: University of Heidelberg
Hypothesis
The study aims to evaluate the prognostic relevance of urokinase plasminogen activator (uPA) detection in disseminated tumor cells in bone marrow of patients with primary breast cancer.
Conclusion
The presence of uPA-positive cells in bone marrow is associated with a significantly shorter metastasis-free interval and overall survival in breast cancer patients.
Supporting Evidence
- 35% of patients with uPA-positive cells in bone marrow developed metastatic disease.
- Patients with uPA-positive cells had a median metastasis-free interval of 36 months.
- Patients with both uPA-positive and 2E11-positive cells had the worst prognosis.
Takeaway
This study found that if breast cancer cells in the bone marrow have a certain marker (uPA), it means the patient might have a worse outcome and may need more aggressive treatment.
Methodology
Bone marrow was sampled from patients and analyzed for the presence of uPA-positive tumor cells using immunocytological staining.
Limitations
The study may not account for all factors influencing metastasis and relies on specific markers that may not capture the full complexity of tumor behavior.
Participant Demographics
The study included 280 patients with primary breast cancer, with a mix of premenopausal and postmenopausal women.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 1.45-5.86 for metastasis-free survival
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website